Impact of Intragastric Balloon Before Bariatric Surgery in BMI ≥ 50 kg/m² Patients

Overview

This retrospective study evaluated the use of intragastric balloon (IGB) placement prior to metabolic bariatric surgery (MBS) in patients with BMI ≥ 50 kg/m². It assessed IGB outcomes, complications, and whether prior IGB influenced surgical weight loss and comorbidity resolution.

Background

Obesity, particularly in patients with BMI ≥ 50 kg/m² (Obesity Class IV/V), is associated with severe comorbidities and increased perioperative risks during bariatric surgery. Metabolic bariatric surgery is the preferred treatment but carries higher complication risks in this population. Intragastric balloon placement is a temporary, mechanical intervention that reduces gastric volume and appetite, potentially serving as a neoadjuvant therapy to improve surgical outcomes. This study investigates the safety and efficacy of IGB as a preparatory step before MBS and its impact on subsequent surgical results.

Data Highlights

The study included adult patients aged 18 to 65 years with BMI ≥ 50 kg/m² undergoing IGB placement before MBS. Balloon volumes ranged from 500 to 800 ml. Follow-up evaluations occurred at 2 weeks, 3 months, and 5 months post-IGB. MBS was scheduled 4 to 8 weeks after balloon removal, with procedures including Roux-en-Y gastric bypass and sleeve gastrectomy performed laparoscopically. Variables analyzed included % total weight loss (%TWL) after IGB and MBS, complications, readmission rates, and comorbidity resolution.

Key Findings

• IGB placement prior to MBS is considered for high-risk patients with BMI ≥ 50 kg/m² to reduce perioperative risks.
• IGB leads to delayed gastric emptying and reduced appetite, facilitating initial weight loss before surgery.
• Complications of IGB include nausea, vomiting, GERD, and respiratory risks related to anesthesia; newer devices aim to reduce these risks.
• Multidisciplinary evaluation and personalized surgical planning optimize patient outcomes post-IGB and MBS.
• Weight loss outcomes and comorbidity improvements after MBS may be influenced by prior IGB, though long-term efficacy of IGB alone is modest.

Clinical Implications

IGB can be a valuable neoadjuvant therapy for patients with severe obesity (BMI ≥ 50 kg/m²) to reduce surgical risks and improve perioperative management. Careful patient selection and multidisciplinary evaluation are essential to optimize outcomes. Clinicians should monitor for IGB-related adverse events and ensure adherence to dietary and follow-up protocols to maximize benefits before proceeding to bariatric surgery.

Conclusion

Intragastric balloon placement prior to metabolic bariatric surgery offers a strategic approach to mitigate risks in patients with extreme obesity. While IGB alone provides modest long-term weight loss, its role as a preparatory step may enhance surgical outcomes and safety in this high-risk population.

References

1. Obesity and Comorbidities References [1-4]
2. Bariatric Surgery Techniques and Outcomes [6,7]
3. Perioperative Risks in Severe Obesity [8,9]
4. Intragastric Balloon Mechanism and Use [9,10,11,12]
5. Weight Loss Calculation Method [13]